Literature DB >> 20926978

Distribution pattern of 68Ga-DOTATATE in disease-free patients.

Manu Shastry1, Irfan Kayani, Damian Wild, Martyn Caplin, Dimitris Visvikis, Svetislav Gacinovic, Jean Claude Reubi, Jamshed B Bomanji.   

Abstract

PURPOSE: 68Ga-DOTA-DPhe1,Tyr3-octreotate (68Ga-DOTATATE) is a somatostatin analogue that shows high affinity for somatostatin receptor subtype 2 (sst2) and has been used for imaging neuroendocrine tumours. However, normal uptake patterns and potential pitfalls have not been described with this high-sensitivity radiotracer. The aim of this study was therefore to outline the normal distribution pattern of 68Ga-DOTATATE in disease-free patients, to provide standardized uptake values (SUVs) of various organs and to compare our results with the current knowledge on sst2 receptor expression in vitro.
METHODS: 68Ga-DOTATATE PET/computed tomography was performed in 42 patients (15 men and 27 women). Approximately 145 MBq of tracer was injected intravenously and imaging was performed using a GE Discovery ST PET/computed tomography scanner. SUVs were calculated on the reconstructed images for various organs.
RESULTS: 68Ga-DOTATATE uptake was noted in the sst2-expressing organs such as pituitary, thyroid, stomach wall, spleen, adrenals, kidneys, pancreas and prostate and in the liver and salivary glands, with excreted activity in the bowel and in the pelvicalyceal system of the kidneys and urinary bladder. The SUVs ranged from 0.1 to 48.8 in the organs considered. Potential pitfalls in interpreting the 68Ga-DOTATATE uptake in organs such as thyroid, pancreas lymph nodes and bowel were identified.
CONCLUSION: This study shows the distribution pattern of 68Ga-DOTATATE outlines the range of SUVs for various organs in disease-free patients and identifies some of the potential pitfalls encountered during imaging.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20926978     DOI: 10.1097/MNM.0b013e32833f635e

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  14 in total

1.  Comparison of ⁶⁸Ga-DOTATATE and ⁶⁸Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours.

Authors:  Levent Kabasakal; Emre Demirci; Meltem Ocak; Clemens Decristoforo; Ahmet Araman; Yıldız Ozsoy; Ilhami Uslu; Bedii Kanmaz
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-04-20       Impact factor: 9.236

2.  68Ga-DOTATOC Embolus Manifestation and Spontaneous Resolution by PET/CT.

Authors:  Akram Al-Ibraheem; Deya' Aldeen Sweedat; Farah Anwer; Feras Istatieh; Malik E Juweid
Journal:  Nucl Med Mol Imaging       Date:  2022-05-12

3.  [68Ga]-DOTATATE PET/CT and PET/MRI in the diagnosis and management of esthesioneuroblastoma: illustrative cases.

Authors:  Michelle Roytman; Andrew B Tassler; Ashutosh Kacker; Theodore H Schwartz; Georgiana A Dobri; Sara B Strauss; Alyssa M Capalbo; Rajiv S Magge; Marissa Barbaro; Eaton Lin; Joseph R Osborne
Journal:  J Neurosurg Case Lessons       Date:  2021-01-11

Review 4.  Potential novel imaging targets of inflammation in cardiac sarcoidosis.

Authors:  Jakob Park; Bryan D Young; Edward J Miller
Journal:  J Nucl Cardiol       Date:  2021-11-03       Impact factor: 3.872

5.  Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation.

Authors:  Jillian Maclean; Matthew Aldridge; Jamshed Bomanji; Susan Short; Naomi Fersht
Journal:  Pituitary       Date:  2014-12       Impact factor: 4.107

6.  Use of full-dose contrast-enhanced CT for extrahepatic staging using Gallium-68-DOTATATE PET/CT in patients with neuroendocrine tumors.

Authors:  Jonas Apitzsch; Frederik Anton Verburg; Felix Mottaghy; Alexander Heinzel
Journal:  Diagn Interv Radiol       Date:  2021-07       Impact factor: 2.630

7.  Twins in spirit part II: DOTATATE and high-affinity DOTATATE--the clinical experience.

Authors:  Claudia Brogsitter; Klaus Zöphel; Holger Hartmann; Margret Schottelius; Hans-Jürgen Wester; Jörg Kotzerke
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-15       Impact factor: 9.236

Review 8.  Prospective of ⁶⁸Ga-radiopharmaceutical development.

Authors:  Irina Velikyan
Journal:  Theranostics       Date:  2013-12-10       Impact factor: 11.556

9.  Gallium-68 DOTA-TATE Positron Emission Tomography/Computed Tomography: Scintigraphic Changes of Adrenal Glands Following Management of Ectopic Cushing's Syndrome by Steroidogenesis Inhibitors.

Authors:  Yu-Ting Huang; Shaikh Irfan Aziz; Aravind S Ravi Kumar
Journal:  World J Nucl Med       Date:  2014-09

10.  Comparative evaluation of 68Ga-labelled TATEs: the impact of chelators on imaging.

Authors:  Yuxiao Xia; Chengrun Zeng; Yanhong Zhao; Xinyi Zhang; Zibo Li; Yue Chen
Journal:  EJNMMI Res       Date:  2020-04-15       Impact factor: 3.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.